1/2 /3-4/ 5-9/Aa-Am/An-Az/B/Ca-Ce/Cf-Cz/Da-Dh/Di-Dz/E/F/G/H/I/J/K/L/M/N/O/Pa-Pf/ /Pj-Po/Pp-Pz/Q/R/Sa-Ss/St-y/Ta-Th/Ti-Tz/U/V/W/X/Y/Z / Chinese spelling
|
|
 |
offer you
better services | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
TRANEXAMIC ACID BP |
DMF IS AVAIBLE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. Tranexamic acid in concentrations up to 10 mg per mL blood has no influence on the platelet count, the coagulation time or various coagulation factors in whole blood or citrated blood from normal subjects. On the other hand, tranexamic acid in concentrations of 10 mg and 1 mg per mL blood prolongs the thrombin time. The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin. Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
We deliver the product to several customers in the chemical and technical industry. Please note the Specification Data of in the following table. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
It is only pointed to the sample certificate of analysis.each batch have difference but meeting BP98 This certificate of analysis is issued according the Original Record 0003544. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Applications | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Packing &loading | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 25KGS NET /DRUMS,28 KGS/ G.W | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
This data is only for your information purposes and does not imply
guarantee for a certain application. Please note: We do not deliver the product to private users! |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| If you need an indicative price to your country, please kindly advise the annual quantity needed, destination port and we will send you our soonest CNF(Cost + Freight) price. Your indication for a workable price level will sure speed up our fastest service for you | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
We really need to get
feed back from our customers in order to improve our performances. Best regards from SHENZHEN , China Mr. JEFFERY TSUI |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Material Safety Data Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Related Information and Active Pharmaceutical Ingredients | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tranexamic acid (marketed in the UK under the trade name of "Cyclokapron") is an antifibrinolytic agent which competitively ... The use of tranexamic acid has superseded the use of amino caproic acid More OHC : Tranexamic acid |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tranexamic Acid Drug Information | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tranexamic acid reduces red cell transfusion better than epsilon | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| If the above information doesn't cover | |
contact us
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
